Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/05/18 | 425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions |
|
5 | |
| 10/18/18 | 8-K | Current report filing |
|
3 | |
| 10/15/18 | DEF 14A | Definitive proxy statements |
|
45 | |
| 10/12/18 | 8-K | Current report filing |
|
3 | |
| 10/11/18 | UPLOAD | SEC-generated letter |
|
1 | |
| 10/09/18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
55 |
| 10/05/18 | UPLOAD | SEC-generated letter |
|
2 | |
| 10/04/18 | 8-K | Current report filing |
|
3 | |
| 09/28/18 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
33 | |
| 09/24/18 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
7 |
